Staff Mobile Engineer

Boehringer Ingelheim and Eko Health inc. launch new AI-based solution that detects heart murmurs in dogs. Ingelheim, Germany and San Francisco, US, Wed, 29/04/2026 - 12:00 * Eko Vet+(TM) | CANINEBEAT(R) AI helps veterinarians detect, visualize, and grade heart murmurs in dogs that can otherwise go undetected * The CANINEBEAT(R) AI algorithm detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity* * With earlier murmur detection, dogs can benefit from heart disease diagnostics and treatment sooner Boehringer Ingelheim, a global leader in animal health, and Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, announced the launch of an innovative solution to detect, visualize, and grade heart murmurs in dogs. Eko Vet+(TM) | CANINEBEAT(R) AI aims to improve health outcomes for dogs with heart disease by enabling veterinarians to identify heart murmurs that might otherwise go unnoticed. "Our proprietary CANINEBEAT(R) AI algorithm integrated into the Eko Vet+(TM) app will powerfully support veterinarians' early detection of heart murmurs in dogs and pet owner conversations," said Dr. Erich Schött, Head of the Pet Business at Boehringer Ingelheim. "Heart murmur detection in dogs can be quite difficult, especially in busy clinics. Because pet owners don't see clinical signs in the early stage of heart disease, it's a challenge for veterinarians to explain that the dog suffers from a serious disease. With this unique AI solution, we can help detect murmurs earlier in the disease process, so dogs may receive appropriate diagnosis and treatment sooner." The new digital solution includes three integrated components: * The Eko CORE(TM) Digital Attachment connects to most single-tube stethoscopes and digitizes heart sounds that can then be analyzed by AI-based algorithms. It also helps veterinarians hear more subtle murmurs by amplifying heart sounds by 40 times and offers advanced noise cancellation and cardiac sound filtering. Other Eko devices also are compatible with the veterinary digital solution. * The CANINEBEAT(R) AI algorithm, trained and validated on more than 4,000 annotated canine heart sound recordings, detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity.* The algorithm is intended to support veterinary clinical assessment and does not replace comprehensive cardiac evaluation or professional veterinary judgment. * The EkoVet+(TM) app incorporates insights from the CANINEBEAT(R) AI algorithm, including murmur images, sound files, and shareable reports. The app provides clinical support and helps veterinarians discuss the potential findings and any diagnostics and treatment needs with pet owners. Heart disease affects approximately 10% of all dogs.[1] The most common heart disease in dogs is myxomatous mitral valve disease (MMVD), which often produces a heart murmur when the heart has a leak in one of the heart valves, preventing blood from getting pumped correctly. MMVD is a chronic condition that is a major cause of morbidity and mortality in dogs.[2] Because dogs in early stages of heart disease may be asymptomatic, heart murmurs can go unnoticed during routine examinations. To address this challenge, 50 global veterinary cardiology experts contributed to the development of Eko Vet+TM with CANINEBEAT(R) AI. "CANINEBEAT(R) AI inside Eko Vet+(TM) is an exceptional resource for general practitioner veterinarians, helping them quickly detect and grade murmurs with a high level of consistency," said Prof. Gerhard Wess, Head of the Cardiology Service, Clinic for Small Animal Internal Medicine, Ludwig-Maximilians-Universität in Munich. "I am thrilled to be involved in the development of this new AI-powered solution that will give veterinarians greater confidence in heart murmur detection and support better outcomes for dogs." The introduction of this innovative auscultation solution for the veterinary industry has begun in the United States and the United Kingdom and will start in Germany next month. A phased expansion is planned in additional markets later this year and next. It will be available through both Boehringer Ingelheim and Eko Health, comprising the same three components through distinct commercial offers. "We've seen firsthand in human health how earlier, more accurate detection of cardiac disease can change the trajectory of care," said Connor Landgraf, CEO and co-founder of Eko Health. "Collaborating with Boehringer Ingelheim, a leader in canine cardiology, allows us to bring that same innovative approach to veterinary medicine. Together, we're equipping veterinarians with AI-powered tools to identify heart murmurs earlier and support better outcomes in canine patients." About Boehringer Ingelheim - Animal Health business. Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health. About Boehringer Ingelheim. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Its approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. About Eko Health. Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, ECG devices, software, and AI-powered analysis. Its FDA-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, California. For more information, visit www.ekohealth.com. Media contacts. Mi-Kyung Lee Lange [email protected] Sam Moore [email protected] Editorial note. * The CANINEBEAT study was conducted using one of the largest canine digital auscultation datasets to date, comprising more than 4,000 heart sound recordings collected from over 3,400 dogs. The study assessed the performance of the CANINEBEAT(R) AI algorithm in detecting canine heart murmurs. All recordings were systematically annotated, with the algorithm's development and validation supported by nearly 50 veterinary cardiology experts. Detailed study results will be presented and published in peer reviewed scientific forums. References. [1] Keene, Bruce W et al. "ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs." Journal of veterinary internal medicine vol. 33,3 (2019): 1127-1140. https://doi.org/10.1111/jvim.15488 [2] Häggström, J et al. "New insights into degenerative mitral valve disease in dogs." Veterinary Clinics of North America: Small Animal Practice. 2004 vol 34, 5: 1209-1226. doi: 10.1016/J.CVSM.2004.05.002. Mi-Kyung Lee-Lange Animal Health Communications Lead

Best board games for kids: by different ages. What You Should Know: - Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for its SENSORA(TM) platform. -The newly issued Category III CPT code will be effective on July 1, 2025, and is the first step to coverage and reimbursement for SENSORA(TM), bringing advanced heart disease detection to clinicians across the U.S. Eko Health: Advancing Early Cardiac Disease Detection with AI-Powered Solutions Eko Health is a leading digital health company revolutionizing the detection and monitoring of heart and lung diseases through its portfolio of digital stethoscopes, patient and provider software, and AI-driven analytics. The company's FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, enables earlier and more accurate detection, confident diagnosis, effective treatment management, and ultimately better patient care. SENSORA: AI-Enhanced Early Disease Detection SENSORA(TM) is an advanced platform that empowers clinicians to detect heart disease earlier, featuring FDA-cleared AI algorithms capable of identifying signs of structural heart murmurs, low ejection fraction (Low EF), and arrhythmias such as AFib in front-line care settings. Key features include: - Seamless integration with the Eko CORE 500(TM) digital stethoscope, which incorporates advanced ECG technology familiar to every provider. - The ability to detect cardiac conditions that are often missed by standard care, supporting early intervention and proactive management. The Critical Role of Early Detection in Heart Disease Management Heart disease remains the leading cause of death in the United States, responsible for approximately 1 in 5 deaths according to the CDC. Early detection is vital for improving patient outcomes. By equipping primary care providers with the tools to identify cardiac issues at an early stage, SENSORA(TM) enhances proactive care, reducing the burden of managing advanced heart disease. Clinical Validation and Impact Eko's AI algorithms have been validated in both clinical and real-world studies: - A clinical trial published in Circulation demonstrated that Eko's AI for structural heart murmur detection doubled the sensitivity for identifying structural heart disease when compared to traditional analog stethoscopes. - In a study published in Lancet Digital Health, involving over 1,000 patients, Eko's low ejection fraction AI accurately detected reduced ejection fraction in primary care settings, leading to its deployment in over 100 clinics in the UK by the NHS and Imperial College London. Expanding Role in Cardiac Care SENSORA's growing significance is further demonstrated by its receipt of the Category III CPT code, which supports its expanding use across various clinical environments. This designation reflects Eko's dedication to equipping primary care clinicians with AI tools that elevate patient care standards and bridge the gap in preventive care. "The AMA's creation of Category III CPT code for Eko's AI disease detection algorithms is a major step in increasing access to early heart disease detection," said Connor Landgraf, CEO of Eko Health. "This milestone will help enable clinicians to use powerful, validated tools to identify heart disease early, ultimately improving patient outcomes, especially in communities with limited access to specialist care."